开年利是来了。 马年启新程，利是纳吉祥。 2025年，是激荡起伏、波澜壮阔的一年。从DeepSeek开年爆火全球所彰显的技术自信，到杭州六小龙掀起的区域创新竞逐，再到港股单日7家IPO的资本 盛况，以及摩尔线程、沐曦股份、智谱等接连上市的热潮，无不印证着这一年，投资人身处浪潮、步履不停。 迈入2026年，投资行业又将驶向何方？流动性格局如何演变，核心赛道蕴藏哪些机遇，投资机构又该如何布局突围...... 新春序曲正酣，年味正浓。值此开年之际，融中汇集一众投资大咖的新春寄语，褪去喧嚣，回归本质，共话2026投资新局。 愿这份开年献礼，为每一位投资同仁、创业伙伴带来期许与启发，策马笃行，并肩向前，共赴新一年的掘金新程。 （按机构名称排序） 2025年我们与香港港投公司联合成立了围绕AI应用领域的投资基金。2026年基金的二期将进入投资期，继续围绕AI产业链进行布局。一个重要方向是坚 持"投早、投小、投新"。但我们也注意到，当前AI领域市场热度偏高，估值出现一定泡沫。因此，在投资过程中，我们将保持谨慎，重点关注项目的成 长性、核心质地、持续经营能力及长期发展潜力。 展望2026年，在募资端，随着宏观经济温和修复，一 ...

据悉，新工产投始终聚焦南京市"2+6+6"创新型产业体系，坚持"三个优先"原则。该基金优先与 集团上市公司联合开展并购投资，撮合集团丰富的上市公司、核心企业产业资源，将围绕重点产业 领域更好地拓展集团核心主业，进行强链、补链、延链和并购投资。 来源：南京新工产投 每日｜荐读 热文： 谁押中了沐曦股份？ 荐读： 2025募资市场年度观察：一年聊过239家LP的真实感受 荐读： 2025年IPO退出盘点：哪些GP赚钱了？ 热文： 投资人"忙疯了" 1月19日，南京新工医疗健康强链并购股权投资基金（有限合伙）完成基金业协会备案。在2026 年1月9日，新工产投于合新工集团、创投集团发起设立规模8亿元的南京新工医疗健康强链并购股 权投资基金，后续拟扩募至20亿元。 ...

Core Viewpoint - The annual venture capital conference highlights the recovery and transformation in the medical investment sector, emphasizing the importance of innovation and strategic investment in the face of changing market dynamics [2][5]. Group 1: Investment Strategies and Focus Areas - Medical investment has shown significant recovery this year, with a notable increase in investment pace by approximately 50% to 60% compared to previous years [6][7]. - Key investment areas include innovative drugs, medical devices, and biomanufacturing, with a focus on projects that demonstrate true innovation capabilities [5][6][8]. - The anticipated influx of new capital, particularly from state-owned enterprises, is expected to drive early-stage project valuations higher in the coming years [7][19]. Group 2: Market Dynamics and Challenges - The medical device sector is currently undergoing a critical phase of import substitution, with many companies experiencing significant growth, particularly in overseas markets [8][9]. - Despite the recovery in the secondary market, challenges remain in the primary market, including ongoing cost control measures and the need for companies to demonstrate profitability [10][11]. - The industry is expected to face a period of consolidation, with some companies likely to exit the market as competition intensifies [8][9]. Group 3: Future Trends and Innovations - The government has prioritized biomanufacturing and related technologies as key future industries, indicating strong support for innovation in the medical sector [9][19]. - Investment in AI and brain-computer interface technologies is gaining traction, with expectations for significant advancements in these areas [26][27]. - The aging population and increasing demand for health and wellness services present substantial opportunities for growth in the medical sector [25][22]. Group 4: Long-term Perspectives and Strategic Adjustments - The focus on long-term innovation and the ability to adapt to changing market conditions are crucial for success in the medical investment landscape [17][35]. - Companies are encouraged to maintain a global perspective and invest in projects with international potential, particularly in the context of limited domestic market growth [18][19]. - Continuous learning and adaptation to new technologies and market trends are essential for sustaining competitive advantage in the medical investment field [17][35].

Core Viewpoint - Zhejiang Jiuzhou Pharmaceutical Co., Ltd. is investing in Jiaxing Longfeng Venture Capital Partnership (Limited Partnership) through its wholly-owned subsidiary, with a total investment amount of RMB 77 million, of which Jiuzhou's contribution is RMB 10 million, accounting for 12.987% of the total [2][4]. Investment Overview - The investment is aimed at sectors related to new drug development and medical device research, focusing on high-quality emerging medical enterprises, including but not limited to new drugs, innovative drugs, medical devices, medical services, diagnostics, biotechnology, and pharmaceutical outsourcing research [2][12]. - The total subscribed capital of the partnership is RMB 77 million, which includes Jiuzhou's investment [4][12]. Partnership Agreement Details - The partnership agreement involves multiple partners, including Shihezi Longtai Equity Investment Management Partnership (Limited Partnership) and others, with Jiuzhou's subsidiary as a limited partner [4][5]. - The partnership has a duration of 6 years, with an investment period of 1.5 years and an exit period of 4.5 years [14]. - The management fee is set at 2% per year based on the total paid-in capital, with no management fee during the extension period [17]. Financial Impact and Strategic Alignment - This investment aligns with the company's overall development strategy and aims to leverage the expertise of professional investment management institutions to expand investment channels and generate returns [21]. - The investment is not expected to have a significant impact on the company's financial and operational status, complying with relevant laws and regulations [21].

Core Insights - The article emphasizes the launch of the 10th cohort of the Medical and Health Future Leadership Class at Shanghai Jiao Tong University, marking a significant milestone in the program's journey and a commitment to innovation in the medical technology sector [4][8][40] - The concept of "From 1 to 0" is introduced, symbolizing a transformative mindset that encourages participants to embrace new beginnings and challenges in the evolving healthcare landscape [10][12][40] Group 1: Program Overview - The 10th cohort's opening ceremony is described as a moment of reflection and ambition, celebrating the program's growth from its inception to its current status [4][8] - The program has evolved into a robust ecosystem that connects various stakeholders in the medical industry, including clinical, capital, and regulatory entities [1][8] - The leadership class aims to cultivate top talent in the medical and health sectors, fostering innovation and collaboration among participants [12][20] Group 2: Key Themes and Messages - The "From 1 to 0" philosophy is highlighted as a call to action for participants to let go of past achievements and focus on future opportunities [10][12] - The importance of maintaining an "empty cup mindset" is stressed, encouraging continuous learning and adaptation in a rapidly changing industry [12][30] - Alumni and industry leaders emphasize the need for deep connections and collaboration to navigate the challenges and opportunities within the medical sector [16][18] Group 3: Alumni Engagement and Community Building - The program fosters a lifelong learning platform, allowing alumni to continuously engage and share knowledge within the medical community [16][20] - The establishment of the Alumni Ecosystem Declaration signifies a commitment to building an inclusive and collaborative medical ecosystem [20][21] - Alumni share insights on the importance of strategic investment and resource integration in driving innovation and addressing industry pain points [18][36]

Core Viewpoint - The company, Boten Co., Ltd. (博腾股份), plans to acquire a portion of shares from Chen Yanxi in the Shenzhen Yifeng Yunding Venture Capital Partnership (Limited Partnership) for a nominal price of 1 yuan, committing to a capital contribution of 20 million yuan as per the partnership agreement [1] Group 1 - The acquisition will allow the company to indirectly invest in the Hangzhou Yifeng Runjun Venture Capital Partnership (Limited Partnership) through the Yifeng Yunding Fund [1] - The Yifeng Runjun Fund primarily focuses on investments in the healthcare sector, including innovative drugs, high-end medical devices, biotechnology, and quality enterprises in related fields both domestically and internationally [1]

Core Viewpoint - The article emphasizes the significant investment opportunities in the Chinese healthcare industry driven by strong policy support and market demand, highlighting a structural transformation from scale expansion to value cultivation [3][26]. Investment Opportunities - The healthcare industry presents two core investment opportunities: "industrial restructuring" and "research and technological innovation," which align with the demand for new and old kinetic energy conversion under existing competition [3][27]. - The investment strategy focuses on early and growth-stage innovative projects, particularly in the fields of innovative drugs and medical technology [8][26]. Company Overview - Sunshine Ronghui Capital, established in January 2015, is one of the first private equity fund managers in the insurance sector, focusing on the healthcare and technology sectors [7][19]. - The company has a management scale exceeding 30 billion yuan and has achieved nearly 20 IPOs, including notable companies like Mindray Medical and Tongyuan Kang Pharmaceutical [4][19]. Investment Strategy - The investment approach is characterized by a comprehensive understanding of the healthcare industry, prioritizing clinical value and health economics, ensuring that investments meet unmet clinical needs while remaining affordable for patients [12][14]. - The company employs a dual approach of extensive research and deep industry engagement, creating a multi-dimensional analysis framework that integrates technology, clinical, and policy market evaluations [15][28]. Ecosystem Development - Sunshine Ronghui Capital has built a comprehensive healthcare ecosystem consisting of three main circles: LPs, enterprises, and the industry, facilitating diverse funding sources and enhancing investment returns [19][20]. - The firm collaborates with local governments to empower regional industries, driving upgrades and supporting key technological breakthroughs [19][20]. Long-term Vision - The company aims to leverage its capital strength to promote the transformation and innovation of the Chinese healthcare industry, aligning with national strategies for high-quality population development [25][28]. - By focusing on sustainable core competitiveness and responding to policy calls, Sunshine Ronghui Capital seeks to ensure that quality healthcare resources benefit a broader population [28].

Core Viewpoint - Rhine Biotech is undergoing a change in control, with the majority of shares being transferred to Guangzhou Defu Nutrition Investment Partnership, while simultaneously planning to acquire at least 80% of Beijing Jinkangpu Food Technology Co., Ltd. [2][4] Group 1: Control Change and Acquisition - Rhine Biotech's controlling shareholder, Qin Benjun, will transfer part of his shares to Guangzhou Defu Nutrition, which will become the new controlling shareholder [2][4] - The acquisition involves purchasing at least 80% of Beijing Jinkangpu's shares, which is expected to enhance Rhine Biotech's competitiveness in the food and health product sectors [6][7] Group 2: Financial Performance and Market Position - Rhine Biotech, known as the "King of Sugar" in China, reported a revenue of approximately 1.272 billion yuan for the first three quarters of the year, reflecting a year-on-year growth of 8.73%, but faced a net profit decline of 30.73% to about 70.4 million yuan due to intense market competition [6] - The sweetener market is showing signs of stagnation, impacting Rhine Biotech's profitability despite revenue growth [6] Group 3: Financial Challenges and Regulatory Issues - The company is under financial pressure, with a significant portion of Qin Benjun's shares pledged, amounting to approximately 1.77 billion shares, representing a pledge ratio of 65.13% [8][9] - Regulatory scrutiny has increased, with the company facing a fine of 600,000 yuan due to a production safety incident and other compliance issues [9]

Core Viewpoint - CATL has re-entered the investment scene by committing 500 million yuan to a new fund managed by Boyu Capital, signaling a recovery in China's venture capital market by the end of 2025 [4][6]. Group 1: Investment Activity - CATL announced its investment of 500 million yuan in the "Boyu New Intelligence New Industry (Ningbo) Equity Investment Partnership," which has a total subscription scale of 4 billion yuan, focusing on technology, healthcare, consumer goods, and retail sectors [6][8]. - Other companies, including Luoyang Molybdenum and Yitai B shares, have also announced their participation in the same fund, indicating a broader interest in this investment opportunity [8]. - The investment by CATL is part of a larger trend where the company is reviving its investment activities after a slowdown in recent years, having previously invested over 2.3 billion yuan in six funds within six months in 2021 [8]. Group 2: Market Sentiment and Trends - The investment by CATL reflects a shift in the overall sentiment of the primary market in 2025, moving away from caution to increased activity among investors [10]. - According to the "LP Panorama Report 2025," the private equity market in China has shown signs of recovery, with a nearly 10% increase in both fundraising and investment activities [10]. - The first three quarters of 2025 saw institutional LPs committing approximately 1.24 trillion yuan, a year-on-year increase of 9%, and the number of newly registered funds rose by 15.18% [10]. Group 3: Return of Institutional Investors - Established institutional investors like Tencent and Alibaba are returning to the market, focusing on future-oriented sectors such as AI and robotics, while new capital from various industries is also entering the equity investment space [11]. - The presence of foreign LPs is re-emerging, with several dollar institutions disclosing new fundraising activities, contributing to overall market confidence [12]. - The return of confidence is creating a positive feedback loop, with policy support for technological innovation and emerging sectors generating new opportunities [12]. Group 4: Long-term Investment Strategy - The current market recovery is characterized by a more patient capital approach, with both old and new investors seeking long-term alignment with industry evolution and national strategies [14]. - CATL's active participation in the LP market not only reflects confidence in its capital allocation but also signifies a clear marker of the primary market's transition into a new development phase [14].

Core Viewpoint - Aipeng Medical (300753.SZ) has signed a partnership agreement to invest in a fund focused on brain-computer interfaces, neuroscience, and mental health, aiming to optimize its industry layout and leverage professional investment resources [1] Group 1: Investment Details - Aipeng Medical will invest RMB 49.7 million as a limited partner, representing a 49.7% stake in the investment fund [1] - The investment is directed towards sectors including brain-computer interfaces, neuroscience, mental health disorders, and other healthcare areas [1] Group 2: Strategic Objectives - The investment aims to accelerate the optimization of the company's industrial layout while ensuring that daily operations and development are not affected [1] - The partnership is designed to effectively control investment risks while leveraging the strengths of professional investment institutions [1]